Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) EBITDA (2019 - 2025)

Historic EBITDA for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to -$26.7 million.

  • aTYR PHARMA's EBITDA fell 4741.22% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.7 million, marking a year-over-year decrease of 1557.32%. This contributed to the annual value of -$67.9 million for FY2024, which is 2366.21% down from last year.
  • Per aTYR PHARMA's latest filing, its EBITDA stood at -$26.7 million for Q3 2025, which was down 4741.22% from -$20.3 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's EBITDA ranged from a high of -$8.0 million in Q4 2022 and a low of -$26.7 million during Q3 2025
  • Moreover, its 4-year median value for EBITDA was -$15.8 million (2024), whereas its average is -$15.7 million.
  • Over the last 5 years, aTYR PHARMA's EBITDA had its largest YoY gain of 650.01% in 2023, and its largest YoY loss of 10074.21% in 2023.
  • Quarter analysis of 4 years shows aTYR PHARMA's EBITDA stood at -$8.0 million in 2022, then crashed by 100.74% to -$16.0 million in 2023, then grew by 0.87% to -$15.8 million in 2024, then plummeted by 69.06% to -$26.7 million in 2025.
  • Its last three reported values are -$26.7 million in Q3 2025, -$20.3 million for Q2 2025, and -$15.8 million during Q1 2025.